Mission & Vision
Help us raise HOPE for the Hopeless for the promise of more tomorrows.
The Hope Promise’s goal is to fund the trial research for an experimental drug option for sarcoma patients. We need your help in making it more affordable so families don’t have the financial burden alongside of the emotional, heart heavy burden they are already experiencing. It’s time to fight for those who are running out of time. Help us raise hope for the hopeless, for the promise of more tomorrows.
Sarcoma is currently a death sentence unless it’s diagnosed as a childhood cancer. As St Jude is the place for childhood cancers, MD Anderson is that for adult cancers.
Joseph Ludwig, M.D.
Associate professor of Sarcoma Medical Oncology at UT (Texas) MD Anderson Cancer Center
About Dr. Ludwig, M.D.
Dr. Ludwig is an associate professor of Sarcoma Medical Oncology at The University of Texas MD Anderson Cancer Center. He joined our faculty ranks in 2006. His research spans a range of interests, from basic science (developmental biology and epigenetics) to translational work (how sarcoma responds to biologically-targeted therapies).
Many of his projects explore how tumor microenvironmental cues — particularly biophysical forces and the extracellular matrix — regulate the spatial organization, phenotype and differentiation state of bone sarcomas, with a major focus on how those parameters affect the sensitivity of Ewing sarcoma to new therapeutic ideas.
Dr. Ludwig’s work has enhanced the field’s understanding of the IGF-1R/mTOR pathway, and his expertise in Ewing sarcoma modeling is changing the way related studies are conducted. As a true physician-scientist, Dr. Ludwig is equally comfortable in the laboratory and clinic.
Because our institution sees perhaps the world’s largest volume of Ewing sarcoma patients, it affords him the opportunities to 1) ensure our engineered models are designed and optimized to maintain high fidelity to human tumors, and 2) enable rapid evaluation of scientific discoveries in early-phase clinical trials. A recent focus has been development of a clinical trial arm for sarcoma patients who will receive treatment with a new microdevice.
This technology allows investigators to safely test up to 16 treatments at once and receive almost immediate feedback on their effectiveness. Dr. Ludwig earned his bachelor’s degree in business administration at the University of Iowa and stayed in the state to pursue his medical degree at the University of Iowa College of Medicine. He completed a residency in internal medicine and a fellowship in molecular therapeutics at the Mayo Graduate School of Medicine in Jacksonville, Florida and received advanced oncology training at the National Cancer Institute in Bethesda, Maryland.
He is the author of numerous articles in respected, peer-reviewed journals and lead investigator on several grant-supported projects. His honors include a Young Investigator Award from the American Society of Clinical Oncology and a Fellows Award in Research Excellence from the National Institutes of Health.